BlackThorn Selected as a Fierce15 2017 Winner

September 26, 2017

BlackThorn Therapeutics has been selected as one of the “Fierce 15” winners for 2017. With this designation, BlackThorn is considered one of the “up-and-coming privately-held biotech companies expected to make big waves in the industry.” The annual Fierce 15 list celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition.


This year, FierceBiotech evaluated a record number of nominations submitted by readers and editors of the publication, and selected the winners based on a variety of factors, including strength of technology, partnerships, venture backers and a competitive market position. FierceBiotech’s full list of winners can be found here.

With a strong financial position, novel approach to CNS drug development, and robust pipeline of first- and best-in-class treatments, the company is well positioned to achieve its goal of becoming a leading neurobehavioral health company – and, importantly, to move toward a future where patients with neurobehavioral disorders are effectively treated.

Share on Facebook
Share on Twitter
Please reload

Featured Posts
  • Multi-Target Collaboration Leverages Vividion's Screening Platform to Discover and Develop Highly Selective Small Molecules for E3 Ligases and Sel...

Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases

May 19, 2020

Please reload

Recent Posts
Please reload

Please reload